New Therapeutic Strategy Minimizes Fragile X Cognitive, Behavioral Defects in Mice
A new pharmacological strategy was able to minimize many cognitive and behavioral defects in mice with fragile X syndrome.
Researchers now believe this may be a promising therapeutic strategy for this disease and other brain disorders.
The findings from the study, “Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model,” was recently published in Neuropsychopharmacology.
Gary Bassell, PhD, professor and chair of cell biology at Emory University School of Medicine, was quoted in this story. He is also a faculty member in the BCDB and NS programs.